

SRH R&D MATRIX

		Basic research	Drugs	Microbicides	Vaccines	Biologics	Diagnostics	Devices & combinations
Contraception	On-demand*	-	✓	-	-	-	-	✓
	Short-acting†	-	✓	-	✓	✓	-	✓
	Long-acting reversible (LARC)‡	-	✓	-	✓	✓	-	✓
	Permanent§	-	✓	-	-	-	-	✓
	Multiple or unspecified duration	-	✓	-	✓	✓	-	✓
HIV/AIDS		<u>Restricted</u>	<u>Restricted</u>	✓	✓	<u>Restricted</u>	✓	-
Sexually transmitted infections (STIs)	Syphilis	<u>Restricted</u>	<u>Restricted</u>	✓	✓	✓	<u>Restricted</u>	-
	Gonorrhoea	<u>Restricted</u>	<u>Restricted</u>	✓	✓	✓	✓	-
	Chlamydia	<u>Restricted</u>	-	✓	✓	✓	✓	-
	Herpes simplex virus 2 (HSV-2)	<u>Restricted</u>	✓	✓	✓	✓	✓	-
	Human T-lymphotropic virus 1 (HTLV-1)	✓	✓	✓	✓	✓	✓	-
	Hepatitis B	<u>Restricted</u>	<u>Restricted</u>	-	-	<u>Restricted</u>	✓	-
	Multiple STIs**	<u>Restricted</u>	<u>Restricted</u> ††	-‡‡	✓	✓	✓	-
	Other STIs§§	<u>Restricted</u>	✓	✓	✓	✓	✓	-
Multipurpose prevention technologies (MPTs)		-	✓	✓	-	-	-	✓
Human papillomavirus (HPV) and HPV-related cervical cancer		<u>Restricted</u>	<u>Restricted</u>	✓	<u>Restricted</u>	✓	✓***	✓†††
Post-partum haemorrhage (PPH)		-	✓	-	-	-	-	<u>Restricted</u>
Pre-eclampsia and eclampsia		<u>Restricted</u>	<u>Restricted</u>	-	-	✓	✓	-
Investment applicable to more than one SRH issue, or to more than one global health area#								
Platform technologies						Core funding of an SRH R&D organisation		
Adjuvants & immunomodulators		Drug delivery technologies & devices		Vaccine delivery technologies & devices				
✓		✓		✓				

✓ denotes a category where a disease or product is included in the survey

Restricted denotes a category where only some investments are eligible

The G-FINDER project covers three global health areas: neglected diseases, emerging infectious diseases, and sexual & reproductive health issues

* On-demand: methods that require action at the time of intercourse or pericoitally for efficacy (e.g. emergency contraception)

† Short-acting: methods that work for < 1 year but do not require action at the time of intercourse (e.g. injectable hormones)

‡ LARC: long-acting reversible contraceptives that work for ≥ 1 year (e.g. implants; IUDs)

§ Permanent: irreversible methods

** Multiple STIs: two or more STIs, including but not limited to chlamydia, gonorrhoea, syphilis, and HIV

†† Includes therapeutic drugs for the treatment of two or more STIs. Preventive drugs that address two or more STIs are captured under the MPT section (MPTs > drugs)

‡‡ Microbicides for the treatment of two or more STIs are in scope, but are captured under the MPT section (MPTs > microbicides)

§§ Other STIs: STIs that disproportionately affect populations in LMICs, including but not limited to trichomoniasis, chancroid, *Mycoplasma genitalium*, lymphogranuloma venereum, and granuloma inguinale (donovanosis)

*** Includes both diagnostics for HPV infection and diagnostics for cervical lesions

††† Includes devices that either clear HPV infection or treat cervical lesions